论文部分内容阅读
目的研究肾移植术后应用普乐可复免疫抑制治疗的临床疗效和毒副作用。方法随机将62例肾移植受者分成两组:(1)FK506组(n=24):应用FK506+骁悉(MMF)+强的松(Pred)治疗方案;(2)环孢素A(CsA)组(n=38):应用CsA+MMF+Pred治疗方案。结果随访24个月,FK506组有2例(8.3%)、CsA组有9例(23.7%)发生急性排斥反应(P<0.05);两组肾功能恢复指标血清肌酐值无明显差异(P>0.05);FK506组和CsA组分别有3例(12.5%)和14例(36.8%)发生肝功能损害(P<0.05);分别有13例(54.2%)和22例(57.9%)血压升高(P>0.05);分别有4例(16.67%)和6例(15.79%)血糖升高(P>0.05)。结论 FK506具有强效的免疫抑制作用,对于发生急性排斥反应、严重肝功能损害等肾移植术后患者由CsA切换成FK506治疗是安全有效的;应用时须根据血药浓度调整剂量,以减少不良反应的发生。
Objective To study the clinical efficacy and side effects of diprivanac immunosuppressive therapy after renal transplantation. Methods 62 renal transplant recipients were randomly divided into two groups: (1) FK506 group (n = 24): FK506 + Prednisone treatment regimen; (2) CsA ) Group (n = 38): CsA + MMF + Pred treatment regimen was used. Results After 24 months follow-up, there were 2 cases (8.3%) in FK506 group and 9 cases (23.7%) in CsA group (P <0.05). There was no significant difference in serum creatinine between the two groups (P> 0.05). There were 13 cases (54.2%) and 22 cases (57.9%) of hepatic dysfunction in 3 cases (12.5%) and 14 cases (36.8%) in FK506 group and CsA group (P> 0.05). There were 4 cases (16.67%) and 6 cases (15.79%) respectively with elevated blood glucose (P> 0.05). Conclusions FK506 has a potent immunosuppressive effect. It is safe and effective to switch from CsA to FK506 after renal transplantation in patients with acute rejection, severe liver dysfunction, etc. The dose of FK506 should be adjusted according to the plasma concentration to reduce the adverse reactions The reaction occurred.